Dr Reddy's Laboratories, second largest Indian pharma major after Sun Pharmaceuticals with net sales of Rs.
13,200 crore plus, has received setback during the third quarter ended
December 2014 on account of higher R&D expenditure and higher tax
provisions. The company's consolidated net profit declined by 7.1 per
cent to Rs. 575 crore from Rs. 619 crore in the corresponding period of last year despite higher finance income of Rs. 101 crore as compared to Rs. 1.47 crore in the previous period.
Though the overall performance was under pressure, DRL scrip moved up smartly by over 4 per cent or over Rs. 130 in the afternoon session on BSE to Rs. 3,366.
The consolidated net sales improved by 8.7 per cent to Rs. 3,843 crore from Rs. 3,534 crore in the similar quarter of last year. Its sales of global generic went up by 7.8 per cent to Rs. 3,169 crore from Rs. 2,940 crore and that of pharmaceutical services & active ingredients (PSAI) improved by 22.1 per cent to Rs. 799 crore from Rs. 654 crore. However, the sales from proprietary products declined by 18.8 per cent to Rs. 39 crore from Rs. 48 crore and other sales declined by 40.2 per cent to Rs. 24 crore from Rs. 40 crore.
The revenues from North America increased by 4 per cent to Rs. 1680 crore. The company launch limited competition products namely decitabine, azacitidine and divalproex sodium ER and expanding market share of key molecules namely ziprasidone, amlodipine-atorvastatin and sumatriptan auto injector. It launch 6 new products during the quarter ended December 2014. It filed 2 ANDas and 68 ANDAs are pending for approval with US FDA. Out of this 13 are 'First to File' status.
Though the overall performance was under pressure, DRL scrip moved up smartly by over 4 per cent or over Rs. 130 in the afternoon session on BSE to Rs. 3,366.
The consolidated net sales improved by 8.7 per cent to Rs. 3,843 crore from Rs. 3,534 crore in the similar quarter of last year. Its sales of global generic went up by 7.8 per cent to Rs. 3,169 crore from Rs. 2,940 crore and that of pharmaceutical services & active ingredients (PSAI) improved by 22.1 per cent to Rs. 799 crore from Rs. 654 crore. However, the sales from proprietary products declined by 18.8 per cent to Rs. 39 crore from Rs. 48 crore and other sales declined by 40.2 per cent to Rs. 24 crore from Rs. 40 crore.
The revenues from North America increased by 4 per cent to Rs. 1680 crore. The company launch limited competition products namely decitabine, azacitidine and divalproex sodium ER and expanding market share of key molecules namely ziprasidone, amlodipine-atorvastatin and sumatriptan auto injector. It launch 6 new products during the quarter ended December 2014. It filed 2 ANDas and 68 ANDAs are pending for approval with US FDA. Out of this 13 are 'First to File' status.
NEW
DELHI: Torrent Pharmaceuticals plans to raise up to Rs 10,000 crore by
issuing securities and will seek shareholders' nod in this regard.
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualif ..
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualif ..
Read more at:
http://economictimes.indiatimes.com/articleshow/46046565.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
http://economictimes.indiatimes.com/articleshow/46046565.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
NEW
DELHI: Torrent Pharmaceuticals plans to raise up to Rs 10,000 crore by
issuing securities and will seek shareholders' nod in this regard.
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualif ..
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualif ..
Torrent
Pharmaceuticals plans to raise up to Rs 10,000 crore by issuing
securities and will seek shareholders' nod in this regard.
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualified Institu ..
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualified Institu ..
Torrent
Pharmaceuticals plans to raise up to Rs 10,000 crore by issuing
securities and will seek shareholders' nod in this regard.
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualified Institu ..
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualified Institu ..
Torrent
Pharmaceuticals plans to raise up to Rs 10,000 crore by issuing
securities and will seek shareholders' nod in this regard.
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualified Institu ..
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualified Institu ..
Read more at:
http://economictimes.indiatimes.com/articleshow/46046565.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
http://economictimes.indiatimes.com/articleshow/46046565.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Torrent
Pharmaceuticals plans to raise up to Rs 10,000 crore by issuing
securities and will seek shareholders' nod in this regard.
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualified Institu ..
The proposals were cleared by the company's board during its meeting today.
With regard to the fund raising plans, the company would put forward enabling resolutions before the shareholders, it said in a filing to the BSE.
The Ahmedabad-based firm plans to allot "equity shares including convertible bonds/debentures through Qualified Institu ..
No comments:
Post a Comment